Mes: enero 2021

BETHESDA, Maryland, 12 de enero de 2021 /PRNewswire-HISPANIC PR WIRE/ — Las mujeres que usan marihuana pueden tener más dificultades para concebir un niño que quienes no la consumen, según sugiere un estudio realizado por investigadores de los Institutos Nacionales de Salud (NIH por sus siglas en inglés). El uso de la marihuana entre las parejas de la mujeres -que podría haber influido en las tasas de concepción- no fue estudiado. El estudio fue dirigido por Sunni L. Mumford, Ph.D., de la División de Epidemiología del Instituto Nacional de la Salud Infantil y Desarrollo Humano Eunice Kennedy Shriver de los NIH. El estudio aparece en la sección Reproducción humana.

Las mujeres eran parte de un grupo más grande que intentaba concebir tras uno o dos abortos espontáneos previos. Las mujeres que dijeron haber consumido productos de cannabis (marihuana o hachís) en las semanas previas al embarazo, o cuyas pruebas de orina dieron positivas para el uso de cannabis, tuvieron alrededor de 40% menos posibilidades de concebir en cada ciclo mensual que las mujeres que no consumían cannabis. Los autores observaron que, aunque los hallazgos sugieren que el cannabis podría afectar la fertilidad de las mujeres, deben tomarse con precaución, ya que el estudio observó un número relativamente reducido de usuarias de cannabis. Sin embargo, los autores declaran que sus resultados sugieren que las mujeres que intentan concebir deberían tener cuidado con el consumo de cannabis hasta que se disponga de pruebas más definitivas.

Los investigadores analizaron datos de un estudio más amplio de más de 1.200 mujeres entre 18 y 40 años de edad, con una o dos pérdidas de embarazos. Las mujeres participaron del estudio durante hasta seis ciclos mensuales mientras intentaban quedar embarazadas, y durante todo el embarazo si se produjo la concepción. Una vez inscritas en el estudio, las mujeres respondieron un cuestionario que les preguntaba si habían consumido marihuana, hierba o hachís en los 12 meses anteriores, con «nunca», «rara vez», «ocasionalmente», «a veces», «a menudo» y «a diario» como opciones de respuesta. Además, cada mujer aportó muestras de orina para su análisis al ingresar al estudio y seis meses después si no lograron concebir, o en el momento de una prueba positiva de embarazo si pudieron concebir.

Un total de 62 mujeres (5%) tuvieron resultados positivos en la prueba de orina o declararon haber usado cannabis antes de la concepción.

En cada ciclo mensual, las mujeres que habían usado cannabis mientras intentaban concebir tuvieron 41% menos posibilidades de concebir que las mujeres que no habían consumido. Del mismo modo, la cantidad de mujeres usuarias de cannabis que quedaron embarazadas durante el estudio fue inferior al de las mujeres que no consumieron: un 42% frente a un 66%. Los autores no encontraron diferencias en las tasas de abortos espontáneos entre usuarias y no usuarias que habían logrado el embarazo.

Los autores han notado que, en comparación con las no usuarias, las mujeres que consumieron cannabis también tuvieron diferencias en cuanto a las hormonas reproductivas involucradas en la ovulación. Estas diferencias podrían potencialmente haber influido en sus posibilidades de concepción. En particular, las usuarias tenían niveles más altos de la hormona luteinizante y una mayor proporción de hormona luteinizante con respecto a la hormona folículoestimulante.

Los autores también informaron que los estudios en animales habían revelado que el uso de cannabis podría alterar el revestimiento interno del útero, disminuyendo la posibilidad de que se implante un embrión para establecer un embarazo. Los autores afirman que, hasta que haya más información disponible, las mujeres que intenten quedar embarazadas deberían estar al tanto de que el cannabis podría potencialmente afectar sus posibilidades de embarazo.

Referencia
Mumford S.L. y otros, «Cannabis use while trying to conceive: a prospective cohort study evaluating associations with fecundability, live birth, and pregnancy loss» (Uso de cannabis mientras se intenta concebir: un estudio prospectivo de cohortes para evaluar las asociaciones con la capacidad de fecundación, los nacimientos vivos y la pérdida de embarazos). Human Reproduction. 2020. DOI:10.1093/humrep/deaa355

Acerca del Instituto Nacional de Salud Infantil y Desarrollo Humano Eunice Kennedy Shriver (NICHD): El NICHD lidera la investigación y la capacitación para comprender el desarrollo humano, mejorar la salud reproductiva, mejorar la vida de niños y adolescentes, y optimizar las habilidades para todos. Si desea más información, visite https://espanol.nichd.nih.gov. 

Acerca de los Institutos Nacionales de la Salud (NIH): NIH, la agencia de investigación médica de los EE. UU., incluye 27 institutos y centros, y es un componente del Departamento de Salud y Servicios Humanos de los EE. UU. NIH es la principal agencia federal que realiza y apoya investigaciones médicas básicas, clínicas y traslacionales, y que investiga las causas, los tratamientos y las curas para enfermedades comunes y raras. Para obtener más información sobre los NIH y sus programas, visite https://salud.nih.gov.

FUENTE Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institutes of Health (NIH)

NEW YORK, Jan. 12, 2021 /PRNewswire/ — New strategic research from Mercer focuses on what the coming year holds for alternatives, outlining some of the issues investors may want to follow closely in an effort to optimize their portfolios.

«We are seeing that though investors have been tested this year, the experiences of previous crises have made them more resilient. There were unorthodox challenges such as not being able to vet new managers in person, but clients continued to put capital to work, especially with existing investment manager relationships across all private market segments,» said Raelan Lambert, global head of alternatives at Mercer.

She continued, «In 2021, investors should consider stretching their risk appetites and consider their allocation to real estate. Although the pandemic will continue to challenge the property market, 2021 is likely to be an opportune time for entering the asset class with a medium- to longer-term investment horizon. Initially, investors should prioritize allocations to the largest, most-liquid markets, where price discovery is furthest along.»

The white paper, Private market challenges: Optimizing your portfolio and top considerations for private markets in 2021, includes issues such as:

• Real estate: the state of current market conditions and opportunities to potentially capitalize on post-COVID changes.
• Natural resources: the reasons behind the significant challenges facing the market and the opportunities inherent in the sector.
• Infrastructure: the growth and attractive performance of the market as well as the challenges associated with managing significant market changes.
• Private debt: how the landscape has changed from the global financial crisis to the 2020 pandemic.
• US private equity and venture capital markets: how advice that clients receive from their legal counsels on terms and conditions could potentially misalign with managers’ interests.
• European private equity: how the COVID-19 virus has compounded the uncertainty created by Brexit.
• Asian private equity: the effect of the pandemic and the ongoing political tension between the US and China.

Click here for the full 2021 Private Market Challenges paper.

About Mercer
Mercer believes in building brighter futures by redefining the world of work, reshaping retirement and investment outcomes, and unlocking real health and well-being. Mercer’s more than 25,000 employees are based in 44 countries and the firm operates in over 130 countries. Mercer is a business of Marsh & McLennan (NYSE: MMC), the world’s leading professional services firm in the areas of risk, strategy and people, with 76,000 colleagues and annual revenue of $17 billion. Through its market-leading businesses including Marsh, Guy Carpenter and Oliver Wyman, Marsh & McLennan helps clients navigate an increasingly dynamic and complex environment. For more information, visit www.mercer.com. Follow Mercer on Twitter @Mercer.

Important Notices

References to Mercer shall be construed to include Mercer LLC and/or its associated companies.

© 2020 Mercer LLC. All rights reserved.

This contains confidential and proprietary information of Mercer and is intended for the exclusive use of the parties to whom it was provided by Mercer. Its content may not be modified, sold or otherwise provided, in whole or in part, to any other person or entity without Mercer’s prior written permission.

Mercer does not provide tax or legal advice. You should contact your tax advisor, accountant and/or attorney before making any decisions with tax or legal implications.

This does not constitute an offer to purchase or sell any securities.

The findings, ratings and/or opinions expressed herein are the intellectual property of Mercer and are subject to change without notice. They are not intended to convey any guarantees as to the future performance of the investment products, asset classes or capital markets discussed.

For Mercer’s conflict of interest disclosures, contact your Mercer representative or see http://www.mercer.com/conflictsofinterest.

This does not contain investment advice relating to your particular circumstances. No investment decision should be made based on this information without first obtaining appropriate professional advice and considering your circumstances.  Mercer provides recommendations based on the particular client’s circumstances, investment objectives and needs.  As such, investment results will vary and actual results may differ materially.

Past performance is no guarantee of future results.  The value of investments can go down as well as up, and you may not get back the amount you have invested. Investments denominated in a foreign currency will fluctuate with the value of the currency. Certain investments, such as securities issued by small capitalization, foreign and emerging market issuers, real property, and illiquid, leveraged or high-yield funds, carry additional risks that should be considered before choosing an investment manager or making an investment decision.

Expected Return

Actual performance may be lower or higher than the performance data quoted. Actual statistics may be lower or higher than the statistics quoted.  The expectations for the modelled portfolio are a compilation of return, volatility, and correlation expectations of the underlying asset classes. 

Portfolio expectations are forward looking and reflective of Mercer’s Capital Market Assumptions, as defined by asset class and incorporating return, standard deviation, and correlations. Our process for setting asset class expected returns begins with developing an estimate of the long term normal level of economic growth and inflation. From these two key assumptions, we develop an estimate for corporate earnings growth and the natural level of interest rates. From these values, we can then determine the expected long term return of the core asset classes, equity and government bonds. We combine current valuations with our expectations for long term normal valuations and incorporate a reversion to normal valuations over a period of up to five years. Volatility and correlation assumptions are based more directly on historical experience except in cases in which the market environment has clearly changed.  Manager impact on performance is not incorporated into expectations.  The views expressed are provided for discussion purposes and do not provide any assurance or guarantee of future returns. 

Not all services or solutions mentioned are available in all jurisdictions. Please contact your Mercer representative for more information.

Information contained herein may have been obtained from a range of third party sources. While the information is believed to be reliable, Mercer has not sought to verify it independently. As such, Mercer makes no representations or warranties as to the accuracy of the information presented and takes no responsibility or liability (including for indirect, consequential, or incidental damages) for any error, omission or inaccuracy in the data supplied by any third party.

Investment management and advisory services for U.S. clients are provided by Mercer Investments LLC (Mercer Investments). Mercer Investments LLC is registered to do business as «Mercer Investment Advisers LLC» in the following states: Arizona, California, Florida, Illinois, Kentucky, New Jersey, North Carolina, Oklahoma, Pennsylvania, Texas, and West Virginia; as «Mercer Investments LLC (Delaware)» in Georgia; as «Mercer Investments LLC of Delaware» in Louisiana; and «Mercer Investments LLC, a limited liability company of Delaware» in Oregon.  Mercer Investments LLC is a federally registered investment adviser under the Investment Advisers Act of 1940, as amended. Registration as an investment adviser does not imply a certain level of skill or training. The oral and written communications of an adviser provide you with information about which you determine to hire or retain an adviser. Mercer Investments’ Form ADV Part 2A & 2B can be obtained by written request directed to:  Compliance Department, Mercer Investments, 99 High Street, Boston, MA 02110.

Certain regulated services in Europe are provided by Mercer Global Investments Europe Limited and Mercer Limited.

Mercer Global Investments Europe Limited and Mercer Limited are regulated by the Central Bank of Ireland under the European Union (Markets in Financial Instruments) Regulation 2017, as an investment firm.  Registered officer: Charlotte House, Charlemont Street, Dublin 2, Ireland.  Registered in Ireland No. 416688.  Directors: Sylvia Cronin, Michael Dempsey, Tom Geraghty, Abhishek Krishan, Deborah Mintern, Bruce Rigby (British) and Vincent Sheridan. Mercer Limited is authorized and regulated by the Financial Conduct Authority. Registered in England and Wales No. 984275. Registered Office: 1 Tower Place West, Tower Place, London EC3R 5BU.

Investment management services for Canadian investors are provided by Mercer Global Investments Canada Limited.  Investment consulting services for Canadian investors are provided by Mercer (Canada) Limited.

CONTACT:
Alayna Francis
+44 755 703 1757
Alayna.Francis@mercer.com

View original content:http://www.prnewswire.com/news-releases/covid-19-political-unrest-market-volatility-increase-the-importance-of-private-markets-in-2021-and-beyond-according-to-mercer-research-301206663.html

SOURCE Mercer

WASHINGTON, Jan. 12, 2021 /PRNewswire/ — Following the 2020 elections, and at the dawn of a new Congress and Administration, advocacy powerhouse Capitol Counsel is set to add three new partners to its health care and tax policy practices.

John Jonas and Martha (Martie) Kendrick join Capitol Counsel from the law firm, Akin Gump, where they were partners, serving clients on health care and tax issues in the regulatory, legislative, and administration settings. James (Jim) Davidson comes to the firm from Polsinelli, where he advised clients on health care, tax, and communications policy.

«We are thrilled that John, Martie, and Jim are joining Capitol Counsel. Their expertise and skills will greatly complement our team,» Capitol Counsel Partner, Shannon Finley, said this morning.

John Jonas brings a deep understanding of health care, having led that practice at Akin Gump. He brings strong policy experience across the health care sector, including hospitals, emergency medical services, physician groups, and pharmaceutical companies. During a decade of public service, Jonas was an instrumental fixture in a variety of roles at the House Ways and Means Committee.

Jonas offered, «Issues come and go, but health care and taxes are always in the discussion. We will give our clients the full measure of insight, allowing them to better navigate these currently very choppy waters.»

Martie Kendrick brings over 30 years of experience representing and counseling clients before Congress in virtually every major piece of health care legislation, as well as regulatory and funding issues before agencies within the Department of Health and Human Services. Kendrick’s broad legislative advocacy experience encompasses congressional authorizing and appropriations committees, including the Senate Finance and House Ways and Means Committees.

«With our health systems and companies facing multiple challenges right now, we can expect health care policy to be a central theme in the new Administration. We are excited to be part of the debate and I look forward to getting to work on behalf of our clients,» Kendrick said.

Jim Davidson has worked on taxation, agency regulations, government information policy, consumer policy, media regulation, privacy, regulation of advertising, health care, appropriations, and budget policy. During his time on the Hill, Davidson served as the chief counsel and staff director of the U.S. Senate Judiciary Subcommittee on Administrative Practice and Procedure, and chief counsel of the Senate Governmental Affairs Subcommittee on Intergovernmental Relations.

«There are going to be big, important debates in the coming years. I am excited about the work we can all do together,» Davidson said.

Capitol Counsel partner, former Congressman and House Ways and Means veteran, Dr. Charles Boustany, said the new team members expand the firm’s capacity and capabilities.

«These are some exceptionally talented, deeply knowledgeable people who will offer our clients the highest level of service and expand our capacity to meet the challenges in this dynamic new political environment,» Boustany said.

This is the most recent expansion for the firm as it prepares for the incoming Administration and the new Congress. In November, they announced the addition of Robert Diamond, who was Special Assistant to the President of the United States and Director of Private Sector Engagement in the Obama-Biden White House.

About Capitol Counsel

Capitol Counsel is a full-service, bipartisan and bicameral advocacy firm recognized for its expertise in tax, health care, financial services, energy, commerce, and trade. For more information on Capitol Counsel, please visit our website at www.capitolcounsel.com or contact John D. Raffaelli at (202) 861-3200.

View original content:http://www.prnewswire.com/news-releases/capitol-counsel-expansion-accelerates-301206651.html

SOURCE Capitol Counsel

DALLAS, Jan. 12, 2021 /PRNewswire/ — Alternet Systems, Inc. (USOTC: ALYI) today announced their financing partner, RevoltTOKEN has achieved a major milestone.  RevoltTOKEN CEO Henryk Dabrowski plans to publish an update this Friday, January 15^th, 2021 to detail the milestone and provide the latest update on progress toward the planned ICO to fund the ALYI electric vehicle ecosystem.

For more information and to stay up to date on RevoltTOKEN’s latest developments, please visit www.revolttoken.com.

For more information and to stay up to date on ALYI’s latest developments, please visit www.alternetsystemsinc.com.

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Alternet Systems, Inc. Contact:
Randell Torno
info@lithiumip.com
+1-800-713-0297

View original content:http://www.prnewswire.com/news-releases/alyi-announces-revolttoken-electric-vehicle-ecosystem-milestone-301206639.html

SOURCE Alternet Systems, Inc.